Welcome to our dedicated page for Flexible Solutn news (Ticker: FSI), a resource for investors and traders seeking the latest updates and insights on Flexible Solutn stock.
Flexible Solutions International (FSI) delivers specialty chemical innovations focused on water conservation and sustainable polymer technologies. This dedicated news hub provides investors and industry professionals with verified updates on the company's advancements in evaporation control solutions and eco-friendly chemical applications.
Access real-time announcements covering earnings disclosures, product development milestones, and strategic partnerships. Our curated collection includes regulatory filings, sustainability initiatives, and market expansion updates relevant to FSI's core operations in energy-efficient water treatments and biodegradable industrial polymers.
Key content categories span operational developments in evaporation reduction technologies, new patent filings, international distribution agreements, and environmental compliance achievements. Each update offers insights into how FSI addresses global challenges in resource conservation through scientifically validated chemical solutions.
Bookmark this page to maintain informed perspectives on FSI's progress in specialty chemicals. Combine regular visits with portfolio monitoring tools for comprehensive analysis of the company's market position and technological leadership.
Flexible Solutions International (NYSE-AMERICAN: FSI) reported Q1 2025 financial results, showing a 20% year-over-year revenue decline from $9.2 million in Q1 2024 to $7.4 million in Q1 2025.
The revenue decrease was attributed to two main factors: inventory adjustments by two significant customers and reduced sales in the ENP division, likely due to early purchases in Q4 2024. CEO Dan O'Brien stated these coinciding factors are rare and maintained optimistic growth expectations for FY 2025.
The company, which specializes in biodegradable polymers for oil extraction, detergent ingredients, water treatment, and crop nutrient availability chemistry, will release complete financial results on May 15, 2025, followed by a conference call on May 16, 2025.
Flexible Solutions International (FSI) reported its full year 2024 financial results, showing improved performance over 2023. The company achieved a net income of $3,038,529 ($0.24 per share), up from $2,775,864 ($0.22 per share) in 2023. While sales slightly decreased to $38,234,860 from $38,324,806, operating cash flow significantly improved to $7,082,952 ($0.57 per share) compared to $4,604,320 ($0.37 per share) in 2023.
The company noted a temporary loss of $385,000 related to the sale of units in their Florida FSI's NanoChem division and ENP subsidiary remain the primary revenue drivers, with expanding opportunities in detergent, water treatment, oil field extraction, turf, ornamental, agricultural use, and emerging prospects in food and nutrition supplement manufacturing markets.
Flexible Solutions International (FSI) has signed a significant new contract with a US-based company for food grade manufacturing. The five-year contract, signed on January 7, 2025, includes automatic renewals for up to five additional five-year terms, unless either party provides notice of non-renewal 180 days before term end.
The contract is expected to generate annual revenue between $15 million and $30 million or more. Revenue generation is anticipated to begin in approximately six months, following the expansion of clean room space and installation of necessary equipment at FSI's Illinois facility.
This non-exclusive agreement represents FSI's strategic expansion into the food grade market, building upon their existing portfolio in biodegradable polymers for oil extraction, detergent ingredients, water treatment, and crop nutrient availability chemistry.
Flexible Solutions International (FSI), a developer of biodegradable polymers and environmental technologies, has reported its Q4 and full-year 2024 revenue figures. The company experienced a 3% year-over-year decline in Q4 revenue, dropping from $9.43 million in Q4 2023 to $9.15 million in Q4 2024. Full-year revenue showed minimal change, slightly decreasing from $38.3 million in 2022 to $38.2 million in 2023.
CEO Dan O'Brien attributed Q4 weakness to international agriculture market conditions but expressed optimism for improvement in 2025. Complete financial results will be released after market close on March 31, 2025, followed by a conference call on April 1, 2025.
Flexible Solutions International (FSI) reported strong Q3 2024 financial results with sales of $9.3 million, up 7% from $8.7 million in Q3 2023. Net income reached $611,858 ($0.05 per share) compared to a net loss of $(718,161) ($(0.06) per share) in Q3 2023. The company's 9-month operating cash flow improved to $5.9 million ($0.47 per share) from $3.3 million ($0.26 per share) in 2023. The NanoChem division and ENP subsidiary remain the main revenue drivers, with new opportunities emerging in food products, detergent, water treatment, and agricultural sectors.
Flexible Solutions International, Inc. (NYSE-AMERICAN: FSI), a developer and manufacturer of biodegradable polymers and environmentally friendly technologies, has announced its Q3 2024 revenue. The company reported a 6.5% year-over-year increase in top-line revenue, rising from $8.721 million in Q3 2023 to $9.287 million in Q3 2024.
FSI specializes in products for oil extraction, detergent ingredients, water treatment, crop nutrient availability, nutraceuticals, and water and energy conservation. The complete financial results will be available after market close on November 14, 2024, coinciding with the company's SEC filings. A conference call is scheduled for November 15, 2024, at 8:00 am Pacific Time (11:00 am Eastern Standard Time) to discuss the results.
Flexible Solutions International (NYSE Amex: FSI) reported its Q2 2024 financial results, showing improvement over the previous year. Key highlights include:
- Q2 sales increased by 2% to $10,528,739 compared to $10,331,291 in Q2 2023
- Net income rose to $1,289,796 ($0.10 per share) from $809,865 ($0.07 per share) in Q2 2023
- 6-month operating cash flow improved to $3,853,907 ($0.31 per share) from $3,220,674 ($0.26 per share) in the same period of 2023
The NanoChem division and ENP subsidiary remain the primary revenue and cash flow generators. The company is exploring new opportunities in various sectors to further increase sales.
Flexible Solutions International (NYSE-AMERICAN: FSI) has announced the sale of units in its Florida investment for a total of $6 million, to be paid over five years. The original purchase price was $3.5 million. This transaction is expected to increase FSI's liquidity and support potential growth in its nutrition and food operations.
CEO Dan O'Brien stated that the sale will contribute to FSI's ability to take on significant contracts in the coming months. The new partner in the Florida is expected to expand sales, which could benefit FSI through a retained supply agreement. Increased sales to the Florida are anticipated to begin in the next several quarters.
Flexible Solutions International (NYSE-AMERICAN: FSI), a developer and manufacturer of biodegradable polymers and environmentally safe technologies, has announced its Q2 2024 revenue. The company reported a slight increase in sales, with top-line revenue rising from $10.331 million in Q2 2023 to $10.528 million in Q2 2024, representing a 2% year-over-year growth.
Complete financial results will be released on August 14, 2024, after market close, coinciding with the company's SEC second quarter filings. A conference call is scheduled for August 15, 2024, at 8:00 am Pacific Time (11:00 am Eastern Standard Time) to discuss the results.
Flexible Solutions International (NYSE-AMERICAN: FSI) announced a significant capital expenditure to acquire a production line for vial filling of injectable drugs such as GLP1 for weight loss. The $2.5 million investment secures a nearly-unused production line capable of producing 22.5 million vials per year, reducing the typical wait time and cost for such equipment. The company aims to leverage its existing clean room skills from its food/nutrition division to enter the high-risk, high-reward drug compounding market. CEO Dan O’Brien emphasized the need for de-risking this venture by securing sales and potentially partnering with experienced players in the industry. The company plans to proceed only if the benefits to shareholders outweigh the risks, with a minimum one-year timeframe before production can commence, subject to regulatory approvals.
